APrevent Medical — Stock, Pipeline & Market Cap

Is this your company? Claim your profile to update info and connect with investors.

Private Company

Funding information not available

Overview

APrevent Medical is a private, commercial-stage medical device company specializing in the respiratory and ENT space, with a core focus on treating glottic insufficiency and dysarthria. The company's flagship products are the VOIS Vocal Implant System, a CE-marked and TFDA-approved adjustable long-term implant, and AiSpeak, an intelligible speech conversion SaaS platform for dysarthria patients. Recent milestones include winning the 2024 MedTech Innovator Asia Pacific Grand Finals, securing a $6M Series D funding round led by Taiwania Capital, and receiving prestigious awards in Taiwan and Germany, indicating strong clinical and market validation. APrevent operates with a hybrid business model of medical device sales and software-as-a-service.

RespiratoryENT/Otolaryngology

Technology Platform

Dual-platform: 1) VOIS - an adjustable, long-term laryngeal implant system for glottic insufficiency with post-operative adjustment capability. 2) AiSpeak - a Software-as-a-Service (SaaS) speech conversion platform utilizing signal processing/AI to convert dysarthric speech into intelligible audio output.

Opportunities

The company has significant opportunities in penetrating the large, underserved market for voice restoration and speech disorders, particularly with its first-mover advantage in adjustable laryngeal implants.

Recent regulatory and reimbursement wins in Germany and Taiwan provide a strong foundation for commercial expansion in Europe and Asia.

The dual-platform strategy allows it to address two distinct but related patient populations, creating multiple revenue streams.

Risk Factors

Key risks include the challenge of driving surgeon adoption for a novel implant technique and competing against established treatment paradigms.

Securing FDA clearance and comprehensive reimbursement in major markets like the U.S.

remains a future hurdle with associated costs and uncertainties.

The company also faces execution risk in simultaneously commercializing a hardware implant and a software-as-a-service platform.

Competitive Landscape

In voice implants, APrevent's VOIS competes with temporary injectable fillers (e.g., hyaluronic acid) and other permanent medialization implants, differentiating itself through post-operative adjustability. For dysarthria, AiSpeak enters the competitive field of augmentative and alternative communication (AAC) devices and software, aiming to differentiate with specialized speech conversion technology that may preserve more of the patient's natural vocal character.

More companies in Small Molecule Drugs →More companies in Austria →